Adverse event reporting in publications compared with sponsor database for cancer clinical trials - PubMed (original) (raw)
Comparative Study
. 2006 Aug 20;24(24):3933-8.
doi: 10.1200/JCO.2005.05.3959.
Affiliations
- PMID: 16921045
- DOI: 10.1200/JCO.2005.05.3959
Comparative Study
Adverse event reporting in publications compared with sponsor database for cancer clinical trials
Orit Scharf et al. J Clin Oncol. 2006.
Abstract
Purpose: Prospectively planned collection and analysis of adverse event (AE) data are essential parts of well-conducted clinical trials. The AE data in a trial sponsor's database should be comparable with what is stipulated in the protocol and with the AE data published. We examined whether the published AE data differ from those in the sponsor's database and from the data collection requirements stated in study protocols.
Methods: We searched the National Cancer Institute (NCI) Clinical Data Update System (CDUS) for studies that used the Common Toxicity Criteria version 2.0 and for which a final study publication was available. We extracted from the protocols information pertaining to AE collection and reporting methods and compared it with the methods cited in the article. We also compared the AE data in the trial publication with the AE data submitted by the investigators to CDUS.
Results: We identified 22 studies meeting the criteria for this review. There was considerable inconsistency between AE collection and reporting methods cited in the protocols versus final publications. AE data in the article and CDUS were not identical. Twenty-seven percent of article high-grade AEs could not be matched to agent-attributable AEs in the CDUS. Twenty-eight percent of CDUS high-grade AEs could not be matched to AEs in the corresponding article. In 14 of 22 articles, the number of high-grade AEs in CDUS differed from the number in the articles by 20% or more.
Conclusion: Lack of consistency in and reporting of AEs are associated with NCI database and trial publication AE data discrepancy.
Comment in
- Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
Anderson SJ. Anderson SJ. J Clin Oncol. 2006 Aug 20;24(24):3821-2. doi: 10.1200/JCO.2006.06.9856. J Clin Oncol. 2006. PMID: 16921032 No abstract available. - More thoughts on the reporting of adverse events in cancer clinical trials.
Extermann M. Extermann M. J Clin Oncol. 2007 Mar 1;25(7):918; author reply 918-9. doi: 10.1200/JCO.2006.09.3948. J Clin Oncol. 2007. PMID: 17327621 No abstract available.
Similar articles
- Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
Anderson SJ. Anderson SJ. J Clin Oncol. 2006 Aug 20;24(24):3821-2. doi: 10.1200/JCO.2006.06.9856. J Clin Oncol. 2006. PMID: 16921032 No abstract available. - Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.
Mahoney MR, Sargent DJ, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC. Mahoney MR, et al. J Clin Oncol. 2005 Dec 20;23(36):9275-81. doi: 10.1200/JCO.2004.00.0588. J Clin Oncol. 2005. PMID: 16361625 - Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
Clark JA, Humphries JE, Crean S, Reynolds MW. Clark JA, et al. Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):107-14. doi: 10.1002/pds.1874. Pharmacoepidemiol Drug Saf. 2010. PMID: 20014051 Review. - Supporting quality and patient safety in cancer clinical trials.
Badalucco S, Reed KK. Badalucco S, et al. Clin J Oncol Nurs. 2011 Jun;15(3):263-5. doi: 10.1188/11.CJON.263-265. Clin J Oncol Nurs. 2011. PMID: 21624861 Review.
Cited by
- Chemotherapy-Induced Toxicities and Their Associations with Clinical and Non-Clinical Factors among Breast Cancer Patients in Vietnam.
Nguyen SM, Pham AT, Nguyen LM, Cai H, Tran TV, Shu XO, Tran HTT. Nguyen SM, et al. Curr Oncol. 2022 Oct 31;29(11):8269-8284. doi: 10.3390/curroncol29110653. Curr Oncol. 2022. PMID: 36354713 Free PMC article. - Automated Ascertainment of Typhlitis From the Electronic Health Record.
Miller TP, Li Y, Masino AJ, Vallee E, Burrows E, Ramos M, Alonzo TA, Gerbing R, Castellino SM, Hawkins DS, Lash TL, Aplenc R, Grundmeier RW. Miller TP, et al. JCO Clin Cancer Inform. 2022 Sep;6:e2200081. doi: 10.1200/CCI.22.00081. JCO Clin Cancer Inform. 2022. PMID: 36198128 Free PMC article. - Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Elgarten CW, Thompson JC, Angiolillo A, Chen Z, Conway S, Devidas M, Gupta S, Kairalla JA, McNeer JL, O'Brien MM, Rabin KR, Rau RE, Rheingold SR, Wang C, Wood C, Raetz EA, Loh ML, Alexander S, Miller TP. Elgarten CW, et al. Pediatr Blood Cancer. 2022 Nov;69(11):e29937. doi: 10.1002/pbc.29937. Epub 2022 Sep 9. Pediatr Blood Cancer. 2022. PMID: 36083863 Free PMC article. - A longitudinal assessment of trial protocols approved by research ethics committees: The Adherance to SPIrit REcommendations in the UK (ASPIRE-UK) study.
Speich B, Odutayo A, Peckham N, Ooms A, Stokes JR, Saccilotto R, Gryaznov D, von Niederhäusern B, Copsey B, Altman DG, Briel M, Hopewell S. Speich B, et al. Trials. 2022 Jul 27;23(1):601. doi: 10.1186/s13063-022-06516-1. Trials. 2022. PMID: 35897110 Free PMC article. - Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
Miller TP, Getz KD, Li Y, Demissei BG, Adamson PC, Alonzo TA, Burrows E, Cao L, Castellino SM, Daves MH, Fisher BT, Gerbing R, Grundmeier RW, Krause EM, Lee J, Lupo PJ, Rabin KR, Ramos M, Scheurer ME, Wilkes JJ, Winestone LE, Hawkins DS, Gramatges MM, Aplenc R. Miller TP, et al. Lancet Haematol. 2022 Sep;9(9):e678-e688. doi: 10.1016/S2352-3026(22)00168-5. Epub 2022 Jul 20. Lancet Haematol. 2022. PMID: 35870472 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources